Covaxin

DCGI approves Phase 2 and 3 clinical trial of COVAXIN in the age group of 2 to 18 Years

The National Regulator of the country, the Drugs Controller General of India (DCGI), after careful examination, has accepted the recommendation of Subject Expert Committee (SEC) and accorded permission to conduct the Phase II/III clinical trial of Covaxin (COVID vaccine) in the age group 2 to 18 years, to its manufacturer Bharat Biotech Ltd on 12.05.2021. …

DCGI approves Phase 2 and 3 clinical trial of COVAXIN in the age group of 2 to 18 Years Read More »